This HR+/ HER2-VE Breast Cancer - Pipeline Insight, 2021 provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HR+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70-80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen.
HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don't have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
The companies and academics are working to assess challenges and seek opportunities that could influence HR+/ HER2-VE Breast Cancer R&D. The therapies under development are focused on novel approaches for HR+/ HER2-VE Breast Cancer.
This segment of the HR+/ HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.
BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
There are approx. 40+ key companies which are developing the HR+/ HER2-VE Breast Cancer. The companies which have their HR+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HR+/ HER2-VE Breast Cancer therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/ HER2-VE Breast Cancer drugs.
Geography Covered
- Global coverage
HR+/ HER2-VE Breast Cancer Understanding
HR+/ HER2-VE Breast Cancer: Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70-80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen.
HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don't have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence HR+/ HER2-VE Breast Cancer R&D. The therapies under development are focused on novel approaches for HR+/ HER2-VE Breast Cancer.
HR+/ HER2-VE Breast Cancer Emerging Drugs Chapters
This segment of the HR+/ HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HR+/ HER2-VE Breast Cancer Emerging Drugs
AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.
BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
HR+/ HER2-VE Breast Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HR+/ HER2-VE Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on HR+/ HER2-VE Breast Cancer
There are approx. 40+ key companies which are developing the HR+/ HER2-VE Breast Cancer. The companies which have their HR+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
Phases
This report covers around 50+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
HR+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
HR+/ HER2-VE Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HR+/ HER2-VE Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/ HER2-VE Breast Cancer drugs.
HR+/ HER2-VE Breast Cancer Report Insights
- HR+/ HER2-VE Breast Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
HR+/ HER2-VE Breast Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing HR+/ HER2-VE Breast Cancer drugs?
- How many HR+/ HER2-VE Breast Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for HR+/ HER2-VE Breast Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HR+/ HER2-VE Breast Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HR+/ HER2-VE Breast Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- BeiGene
- H3 Biomedicine
- AstraZeneca
- Olema Pharmaceuticals
- CytomX Therapeutics
- Roche
- G1 Therapeutics
- Sanofi
- Jiangsu HengRui Medicine
Key Products
- BGB-290
- H3B-6545
- AZD9833
- OP-1250
- CX-2009
- RG6171
- Rintodestrant
- Amcenestrant
- SHR6390
Table of Contents
IntroductionExecutive Summary
HR+/ HER2-VE Breast Cancer: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
AZD9833: Astrazeneca
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
BGB-290: BeiGene
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
OP-1250: Olema Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Preclinical Stage Products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
HR+/ HER2-VE Breast Cancer Key Companies
HR+/ HER2-VE Breast Cancer Key Products
HR+/ HER2-VE Breast Cancer- Unmet Needs
HR+/ HER2-VE Breast Cancer- Market Drivers and Barriers
HR+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
HR+/ HER2-VE Breast Cancer Analyst Views
HR+/ HER2-VE Breast Cancer Key Companies
AppendixList of Tables
Table 1 Total Products for HR+/ HER2-VE Breast Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for HR+/ HER2-VE Breast Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BeiGene
- H3 Biomedicine
- AstraZeneca
- Olema Pharmaceuticals
- CytomX Therapeutics
- Roche
- G1 Therapeutics
- Sanofi
- Jiangsu HengRui Medicine
